Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: With No New Offerings, Kadmon Steals The Spotlight

Executive Summary

Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.

You may also be interested in...



IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat

The three most recent biopharma IPOs are trading at or below their offering prices, but the average return for the 22 drug development firms that have gone public so far this year is holding steady at 11% -- thanks to a pair of super performers that have delivered triple-digit returns.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Half of 2016 Biotech IPOs Positive At Mid-Year; 2015 Success Rate Sours

It hasn't been easy for biopharmaceutical firms to go public in the US during 2016, but as of the end of June the scrutiny seems to be paying off – at least for investors in half of this year's first-half initial public offerings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065433

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel